Results 261 to 270 of about 25,353 (314)
Some of the next articles are maybe not open access.

Clonidine transdermal patch poisoning

Annals of Emergency Medicine, 1988
A case of infant clonidine poisoning from a transdermal patch that had been worn for five days by an adult and then discarded is described. The infant became hypotensive with a systolic blood pressure of 38 mm Hg, and a dopamine infusion was required for six hours to maintain adequate blood pressure.
E M, Caravati, D L, Bennett
openaire   +2 more sources

Transdermal Patch Poisoning

Pediatrics, 1987
To the Editor.— We wish to report a case of an accidental ingestion of clonidine from a transdermal patch by a 9-month-old baby. A.M., a 9-month-old boy, was seen in a local emergency room six hours after he had accidentally mouthed a transdermal clonidine patch.
JOAN E. HAMBLIN, CHARLES A. MARTIN
openaire   +1 more source

Ibuprofen Transdermal Patch

2014
Many pain sufferers have difficultly using oral dosages or injections of medications, bringing about the need for an alternative means of delivery for both over the counter and prescription medications. A promising option is medicated patches that can transfer pain relieving drugs through the skin to a localized area.
Gradisher, Logan, Stephens, Analisa
openaire   +1 more source

Rotigotine Transdermal Patch

CNS Drugs, 2008
Rotigotine is a non-ergolinic dopamine receptor agonist, formulated as a silicone-based transdermal patch, which has been evaluated for use in the treatment of adults with moderate to severe restless legs syndrome (RLS). Transdermal rotigotine improved the symptoms of RLS in two well designed 6-month trials in adults with idiopathic, moderate to severe
Claudine M, Baldwin, Gillian M, Keating
openaire   +2 more sources

Skin tolerability of transdermal patches

Expert Opinion on Drug Delivery, 2011
Transdermal patch systems are an effective method of administering active ingredients through the skin, with considerable advantages over other drug delivery routes, for example, maintenance of constant plasma drug levels and avoidance of first-pass metabolism.
Johannes, Wohlrab, B, Kreft, B, Tamke
openaire   +2 more sources

Fentanyl transdermal patches induced chemical leucoderma

BMJ Supportive & Palliative Care, 2021
Chemical leucoderma is defined as hypopigmentation or vitiligo-like hypomelanosis caused by repeated chemical exposure, and the diagnosis can be made clinically. Chemical leucoderma induced by fentanyl transdermal patches is rare. This case report involves a 53-year-old man with chronic back pain caused by herniated nucleus pulposus at the L4–L5 level.
Sanhapan Wattanapisit   +3 more
openaire   +2 more sources

Deaths With Transdermal Fentanyl Patches

American Journal of Forensic Medicine & Pathology, 2010
Fentanyl is a potent Schedule II narcotic analgesic recommended for use in the management of unremitting pain not controlled by morphine or other opiate/opioid drugs. The danger inherent to fentanyl is its potency (greater than 50-100 times that of morphine) and rapidity of action, causing respiratory depression within minutes of administration ...
openaire   +2 more sources

Transdermal Fentanyl Patches in Small Animals

Journal of the American Animal Hospital Association, 2004
Fentanyl citrate is a potent opioid that can be delivered by the transdermal route in cats and dogs. Publications regarding transdermal fentanyl patches were obtained and systematically reviewed. Seven studies in cats and seven studies in dogs met the criteria for inclusion in this review.
Erik H, Hofmeister, Christine M, Egger
openaire   +2 more sources

Fatal misuse of transdermal fentanyl patches

Forensic Science International, 2019
Fentanyl is a potent synthetic opioid with a variety of possible applications. Transdermal fentanyl patches are regularly prescribed for patients with severe chronic or cancer-related pain. The potential for abuse is well-known and cases associated with illicit fentanyl intake are common.
J. Geile   +4 more
openaire   +2 more sources

Childhood Poisoning Involving Transdermal Nicotine Patches

Pediatrics, 1997
Objective. To describe the circumstances, medical complications, and outcomes of children exposed to a transdermal nicotine patch (TNP). Design. Prospective case series; postmarketing surveillance study over a 24-month period. Setting. Thirty-four United States poison centers. Patients.
A, Woolf   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy